Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Bruce R. Carr(University of Florida), Kristof Chwalisż(AbbVie (United States)), Roland Jimenez(Neurocrine Biosciences (United States)), Elizabeth Garner(American Association of University Women), W. Paul Dmowski(Creighton University), Joshua Burke(Neurocrine Biosciences (United States)), Chris O’Brien(Neurocrine Biosciences (United States)), Ping Jiang(AbbVie (United States))
Cited by 113
Related Papers
Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations
|Nature Communications|2015|542
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
|New England Journal of Medicine|2017|492
Deficient cellular immunity in endometriosis
|American Journal of Obstetrics and Gynecology|1981|310
Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis
|Fertility and Sterility|1996|270
Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis
|Human Reproduction|2001|232